Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bimatoprost (lashes) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
Topical cosmetic. Cysteamine 5% cream is typically applied once daily to areas of melasma as a short-contact treatment (left on for ~15 minutes, then washed off) to limit odor and irritation, with daily sunscreen. There is no oral or systemic use in this context. This library does not provide an ingestion protocol.
any
Cysteamine 5% cream (short-contact application)
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
Throughout
8-16 weeks
Throughout
Throughout
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · Rct
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · Rct · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial.
Br J Dermatol (2015) · Rct · n=50
First double-blind placebo-controlled RCT of cysteamine 5% cream for epidermal melasma (n=50), nightly for 4 months
Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study.
J Dermatolog Treat (2018) · Rct · n=40
Second double-blind placebo-controlled RCT (n=40), nightly cysteamine 5% for 4 months, with Dermacatch and Mexameter colorimetry
A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women.
Int J Dermatol (2020) · Rct · n=40
Multicenter evaluator-blinded head-to-head of cysteamine 5% vs hydroquinone 4% (n=40), nightly for 120 days with sunscreen
Bimatoprost (lashes) has a higher evidence score (8/10 vs 6/10) and wins in 2 of 3 categories.
No known interactions between Bimatoprost (lashes) and Cysteamine (topical) have been documented in our database. However, always consult a healthcare provider before combining supplements.